Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...

Lonza said on Friday it does not expect any 'material financial impact' from current and potential pharma-specific tariffs.

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price up by as much as 35% ...

Insilico Medicine files third HKEX IPO attempt, as biotech develops rentosertib for IPF and other drugs with AI-driven ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said ...

The AI-fo­cused biotech in­sitro has laid off 22% of its work­force, the com­pa­ny said in a Thurs­day state­ment. Found­ed ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...